Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $160.5 million.

  • Prime Medicine's Shares Outstanding (Diluted Average) rose 3401.59% to $160.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.5 million, marking a year-over-year increase of 3401.59%. This contributed to the annual value of $118.6 million for FY2024, which is 3037.4% up from last year.
  • Per Prime Medicine's latest filing, its Shares Outstanding (Diluted Average) stood at $160.5 million for Q3 2025, which was up 3401.59% from $129.2 million recorded in Q2 2025.
  • Prime Medicine's Shares Outstanding (Diluted Average)'s 5-year high stood at $160.5 million during Q3 2025, with a 5-year trough of $13.0 million in Q4 2021.
  • Over the past 5 years, Prime Medicine's median Shares Outstanding (Diluted Average) value was $91.0 million (recorded in 2023), while the average stood at $80.5 million.
  • Per our database at Business Quant, Prime Medicine's Shares Outstanding (Diluted Average) skyrocketed by 36752.28% in 2023 and then surged by 838.76% in 2025.
  • Over the past 5 years, Prime Medicine's Shares Outstanding (Diluted Average) (Quarter) stood at $13.0 million in 2021, then soared by 161.23% to $33.9 million in 2022, then soared by 168.42% to $91.0 million in 2023, then soared by 30.37% to $118.6 million in 2024, then skyrocketed by 35.33% to $160.5 million in 2025.
  • Its last three reported values are $160.5 million in Q3 2025, $129.2 million for Q2 2025, and $130.9 million during Q1 2025.